{
  "id": 589479,
  "title": "Short-term risk of falls among initiators of controlled-release tapentadol versus oxycodone in New South Wales between 2014 and 2020: A population-based retrospective cohort study",
  "url": "https://urgent.news/2026/08/11/short-term-risk-of-falls-among-initiators-of-controlled-release",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-11T14:00:00.000Z",
  "source": {
    "name": "PLOS Medicine",
    "slug": "plos-medicine",
    "url": "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004950"
  },
  "original_language": "en",
  "account": null,
  "summary": "by Ximena Camacho, Andrea L. Schaffer, Jonathan Brett, Ria Hopkins, Natasa Gisev, Steven Marsh, Kristian B. Filion, Nicole Pratt, David Henry, Sallie-Anne Pearson Background Clinical trials comparing sustained-release (SR) tapentadol with controlled-release (CR) oxycodone have suggested that tapentadol (SR) may be associated with fewer nervous system side effects. However, it remains important to…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}